|
US6710174B2
(en)
|
2001-09-13 |
2004-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of vascular endothelial growth factor receptor-1 expression
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
US7396664B2
(en)
|
1999-06-08 |
2008-07-08 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
US6833349B2
(en)
*
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
DE60219419T2
(de)
|
2001-01-19 |
2007-08-16 |
Ludwig Institute For Cancer Research |
Flt4 (vegfr-3) als ein ziel für krebsdarstellung und anti-krebs-behandlung
|
|
US6734017B2
(en)
|
2001-09-28 |
2004-05-11 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of vascular endothelial growth factor receptor-2 expression
|
|
DE60336341D1
(de)
|
2002-05-04 |
2011-04-21 |
Acorda Therapeutics Inc |
Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
|
|
DK1608685T3
(da)
*
|
2003-03-28 |
2007-06-11 |
Regeneron Pharma |
VEGF antagonister til behandlingen af diabetes
|
|
ES2831031T3
(es)
*
|
2003-05-16 |
2021-06-07 |
Acorda Therapeutics Inc |
Proteínas de fusión para el tratamiento del CNS
|
|
JP2007532094A
(ja)
|
2003-05-16 |
2007-11-15 |
アコーダ セラピューティクス、インク． |
Ｃｎｓ治療用のプロテオグリカン分解変異体
|
|
US7959914B2
(en)
|
2003-05-16 |
2011-06-14 |
Acorda Therapeutics, Inc. |
Methods of reducing extravasation of inflammatory cells
|
|
EP1626989A2
(en)
*
|
2003-05-28 |
2006-02-22 |
Regeneron Pharmaceuticals, Inc. |
Method of treating corneal transplant rejection by using vegf antagonists
|
|
US7186699B2
(en)
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
|
WO2004110490A2
(en)
*
|
2003-06-06 |
2004-12-23 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitors for tumor regression
|
|
US7399612B2
(en)
|
2003-06-30 |
2008-07-15 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
AR046510A1
(es)
*
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
CA2534197A1
(en)
*
|
2003-08-06 |
2005-02-24 |
Thomas Jefferson University |
Use of a vegf antagonist in combination with radiation therapy
|
|
US8226941B2
(en)
|
2004-05-18 |
2012-07-24 |
Acorda Therapeutics, Inc. |
Methods of purifying chondroitinase and stable formulations thereof
|
|
EP1767546B1
(en)
|
2004-06-08 |
2012-03-07 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Angiogenesis-inhibiting chimeric protein and the use
|
|
CA2567686A1
(en)
|
2004-06-10 |
2005-12-29 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitors for the treatment of human cancer
|
|
WO2006009809A2
(en)
*
|
2004-06-18 |
2006-01-26 |
Regeneron Pharmaceuticals, Inc. |
Vegf inhibitors for the treatment of malignant pleural effusion
|
|
WO2006015297A2
(en)
*
|
2004-07-30 |
2006-02-09 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating type i diabetes by blocking vegf-mediated activity
|
|
WO2006031689A2
(en)
|
2004-09-13 |
2006-03-23 |
Genzyme Corporation |
Multimeric constructs
|
|
FR2878749B1
(fr)
*
|
2004-12-03 |
2007-12-21 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
|
|
EP1877438A2
(en)
|
2005-02-02 |
2008-01-16 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a vegf inhibitor
|
|
LT2586459T
(lt)
|
2005-03-25 |
2017-09-25 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonisto kompozicijos
|
|
ES2393748T3
(es)
|
2005-09-26 |
2012-12-27 |
Acorda Therapeutics, Inc. |
Composiciones y métodos de uso de condroitinasa ABCI mutantes
|
|
NZ568739A
(en)
†
|
2005-12-16 |
2010-09-30 |
Regeneron Pharma |
Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists
|
|
FR2895258B1
(fr)
|
2005-12-22 |
2008-03-21 |
Aventis Pharma Sa |
Combinaison comprenant de la combretastatine et des agents anticancereux
|
|
US8216575B2
(en)
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
|
CN100502945C
(zh)
*
|
2006-03-31 |
2009-06-24 |
成都康弘生物科技有限公司 |
Vegf受体融合蛋白在治疗眼睛疾病中的应用
|
|
CN104434770A
(zh)
|
2006-06-16 |
2015-03-25 |
瑞泽恩制药公司 |
适合玻璃体内施用的vegf拮抗剂的制剂
|
|
PL2066694T3
(pl)
|
2006-09-29 |
2016-04-29 |
Oncomed Pharm Inc |
Kompozycje i sposoby diagnozowania i leczenia nowotworu
|
|
CA3086902C
(en)
|
2006-10-10 |
2021-11-09 |
Acorda Therapeutics, Inc. |
Compositions and methods of using chondroitinase abci mutants
|
|
FR2918279B1
(fr)
*
|
2007-07-05 |
2010-10-22 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
|
|
CN101575379B
(zh)
*
|
2008-05-09 |
2012-05-30 |
上海抗体药物国家工程研究中心有限公司 |
可溶性vegfr双功能融合受体、其制备方法及用途
|
|
CA2742241C
(en)
|
2008-11-03 |
2019-12-10 |
Molecular Partners Ag |
Binding proteins inhibiting the vegf-a receptor interaction
|
|
CN101838329A
(zh)
*
|
2009-03-18 |
2010-09-22 |
嘉和生物药业有限公司 |
抗血管新生融合蛋白
|
|
WO2011047383A1
(en)
|
2009-10-16 |
2011-04-21 |
Oncomed Pharmaceuticals, Inc. |
Therapeutic combination and methods of treatment with a dll4 antagonist and an anti-hypertensive agent
|
|
AR081361A1
(es)
|
2010-04-30 |
2012-08-29 |
Molecular Partners Ag |
Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
|
|
EP3327032A1
(en)
|
2010-08-06 |
2018-05-30 |
Genzyme Corporation |
Vegf antagonist compositions and uses thereof
|
|
EP2662385A4
(en)
*
|
2011-01-07 |
2015-11-11 |
Chugai Pharmaceutical Co Ltd |
METHOD FOR IMPROVING THE PHYSICAL PROPERTIES OF ANTIBODIES
|
|
JP2014503555A
(ja)
|
2011-01-13 |
2014-02-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
KR101397088B1
(ko)
|
2011-06-10 |
2014-05-19 |
강원대학교산학협력단 |
암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
|
|
JO3370B1
(ar)
*
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
|
JP6138815B2
(ja)
|
2011-12-01 |
2017-05-31 |
エーピー バイオサイエンシーズ， インコーポレイテッド |
補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法
|
|
CN103304668B
(zh)
*
|
2012-03-12 |
2015-10-28 |
江苏健德生物药业有限公司 |
Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
|
|
DK2846836T3
(da)
|
2012-05-07 |
2019-11-11 |
Allergan Inc |
Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi
|
|
WO2014006113A1
(en)
|
2012-07-03 |
2014-01-09 |
Sanofi |
Method of treating cancer by effective amounts of aflibercept
|
|
TW201438736A
(zh)
|
2012-11-14 |
2014-10-16 |
Regeneron Pharma |
以ｄｌｌ４拮抗劑治療卵巢癌之方法
|
|
MX368730B
(es)
|
2013-02-18 |
2019-10-14 |
Vegenics Pty Ltd |
Moleculas que unen ligando y usos de las mismas.
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
CN104193828B
(zh)
*
|
2013-09-12 |
2017-04-05 |
北京韩美药品有限公司 |
同时阻断her2和vegfr信号通路的重组融合蛋白
|
|
PT3065761T
(pt)
|
2013-11-05 |
2020-02-21 |
Allergan Inc |
Método de tratamento de condições oculares com um darpin anti-vegf
|
|
CA2947456C
(en)
|
2014-05-12 |
2023-03-14 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
|
JP6685276B2
(ja)
|
2014-07-18 |
2020-04-22 |
サノフイＳａｎｏｆｉ |
癌に罹患していることが疑われる患者のアフリベルセプトを用いた処置の結果を予測するための方法
|
|
JP2016036322A
(ja)
*
|
2014-08-11 |
2016-03-22 |
日本化薬株式会社 |
血管新生因子と結合するキメラタンパク質
|
|
EP3985023A1
(en)
|
2014-12-11 |
2022-04-20 |
Bayer Healthcare LLC |
Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
|
|
GB201503453D0
(en)
|
2015-03-01 |
2015-04-15 |
Jain Arjun |
Endothelin-1"sponge"
|
|
TW202440904A
(zh)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（二）
|
|
WO2017046140A1
(en)
|
2015-09-18 |
2017-03-23 |
Bayer Pharma Aktiengesellschaft |
Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
|
|
KR101936049B1
(ko)
*
|
2015-10-15 |
2019-01-08 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 생산방법
|
|
WO2017065559A1
(ko)
|
2015-10-15 |
2017-04-20 |
(주)알테오젠 |
Igg fc 도메인을 가지는 융합 단백질의 생산방법
|
|
KR20180083377A
(ko)
|
2015-11-18 |
2018-07-20 |
포르미콘 아게 |
Vegf 안타고니스트를 함유하는 사전충전형 플라스틱 주사기
|
|
WO2017087871A1
(en)
|
2015-11-18 |
2017-05-26 |
Sio2 Medical Products, Inc. |
Pharmaceutical package for ophthalmic formulations
|
|
MX2018006092A
(es)
|
2015-11-18 |
2019-01-31 |
Formycon Ag |
Envase farmacéutico precargado que comprende una formulación líquida de un antagonista del vegf.
|
|
EP3377101A4
(en)
*
|
2015-11-19 |
2019-08-07 |
Zhuhai Tairuishang Biopharm Ltd. |
VEGF BINDING METHODS AND COMPOSITIONS
|
|
FI3384049T3
(fi)
|
2015-12-03 |
2023-09-25 |
Regeneron Pharma |
Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä
|
|
AU2017213103B2
(en)
|
2016-01-26 |
2022-08-11 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
|
US20190300607A1
(en)
|
2016-10-12 |
2019-10-03 |
Daiichi Sankyo Company, Limited |
Composition containing anti-robo4 antibody and other agents
|
|
WO2018094316A1
(en)
|
2016-11-21 |
2018-05-24 |
Just Biotherapeutics, Inc. |
Aflibercept formulations and uses thereof
|
|
WO2018217995A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
US20200171244A1
(en)
|
2017-05-24 |
2020-06-04 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
CN111344410B
(zh)
|
2017-08-17 |
2023-09-15 |
济世易为生物有限公司 |
从宿主细胞半乳糖凝集素和其他污染物中纯化糖基化蛋白的方法
|
|
JP7183268B2
(ja)
|
2017-11-20 |
2022-12-05 |
ジャスト－エヴォテック バイオロジックス、インコーポレイテッド |
等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
|
|
BR112020010674A2
(pt)
*
|
2017-11-27 |
2020-11-10 |
4D Molecular Therapeutics Inc. |
capsídeos de variante de vírus adeno-associado e uso para inibir a angiogênese
|
|
ES2927049T3
(es)
|
2017-11-30 |
2022-11-02 |
Regeneron Pharma |
Uso de un antagonista del VEGF para tratar trastornos oculares angiogénicos
|
|
WO2019118187A1
(en)
*
|
2017-12-13 |
2019-06-20 |
Regeneron Pharmaceuticals, Inc. |
Devices and systems for chromatography column bed support management and related methods
|
|
DK3743091T3
(da)
|
2018-01-26 |
2025-01-06 |
Univ California |
Fremgangsmåder og sammensætninger til behandling af angiogene lidelser under anvendelse af anti-vegf-midler
|
|
MX2020009152A
(es)
|
2018-03-02 |
2020-11-09 |
Kodiak Sciences Inc |
Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
|
|
PT4364724T
(pt)
|
2018-05-10 |
2025-12-16 |
Regeneron Pharma |
Formulações contendo uma proteína de fusão do recetor do vegf de concentração elevada
|
|
TW202016125A
(zh)
*
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
CN111378044B
(zh)
|
2018-12-28 |
2022-07-15 |
长春金赛药业有限责任公司 |
抗体融合蛋白、制备方法及其应用
|
|
EP3969564A1
(en)
|
2019-05-16 |
2022-03-23 |
Formycon AG |
Method for reducing methionine oxidation in recombinant proteins
|
|
AU2020343242A1
(en)
|
2019-09-03 |
2022-03-10 |
Amgen Inc. |
Injection device for drug delivery and packaging for the injection device
|
|
CA3150482A1
(en)
|
2019-09-16 |
2021-03-25 |
Amgen Inc. |
Method for external sterilization of drug delivery device
|
|
WO2021072265A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
CA3168512A1
(en)
|
2019-11-25 |
2021-06-03 |
Napoleone Ferrara |
Long-acting vegf inhibitors for intraocular neovascularization
|
|
JP2023505216A
(ja)
|
2019-12-06 |
2023-02-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｖｅｇｆミニトラップおよびそれらの使用方法
|
|
EP3906303A1
(en)
*
|
2019-12-06 |
2021-11-10 |
Regeneron Pharmaceuticals, Inc. |
Anti-vegf protein compositions and methods for producing the same
|
|
CA3167020A1
(en)
|
2020-02-24 |
2021-09-02 |
Amgen Inc. |
Containers and systems for use during external sterilization of drug delivery devices
|
|
CA3182893A1
(en)
|
2020-05-08 |
2021-11-11 |
Regeneron Pharmaceuticals, Inc. |
Vegf traps and mini-traps and methods for treating ocular disorders and cancer
|
|
BR112023022439A2
(pt)
|
2021-04-26 |
2023-12-26 |
Celanese Eva Performance Polymers Llc |
Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
|
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
|
US20250002557A1
(en)
|
2021-11-24 |
2025-01-02 |
Suzhou Light Ferry Biomed. Co., Ltd |
Multi-specific ligand-binding molecules and applications thereof
|
|
EP4549455A1
(en)
*
|
2022-08-02 |
2025-05-07 |
Panolos Bioscience, Inc. |
Modified fusion protein and use thereof
|
|
KR20250065646A
(ko)
|
2022-09-16 |
2025-05-13 |
치루 파머수티컬 컴퍼니 리미티드 |
안정적인 고농도 자가완충식 약물 조성물
|
|
WO2025033876A1
(ko)
*
|
2023-08-04 |
2025-02-13 |
주식회사 파노로스바이오사이언스 |
변형된 융합 단백질과 scFv의 결합체 및 이의 용도
|
|
WO2025213011A1
(en)
|
2024-04-05 |
2025-10-09 |
Amgen Inc. |
Method of assessing stopper movement in a drug delivery device
|